Butterfly Network Inc Stock Price, News & Analysis

Butterfly Network (NYSE:BFLY) reported strong Q2 2025 financial results, achieving its highest quarterly revenue of $23.4 million, representing 9% year-over-year growth. The company reached record gross margins of 64% and reduced quarterly cash burn to a historic low of $7.1 million.

Key highlights include U.S. revenue of $17.2 million and international revenue growth of 19% to $6.2 million. The company revised its full-year 2025 guidance to revenue of $91-95 million (13% growth) and improved Adjusted EBITDA loss guidance to $32-37 million.

Additionally, BFLY announced the resignation of CFO Heather Getz, with Chief Accounting Officer Megan Carlson assuming interim financial leadership roles. The company is preparing to launch its next-generation Compass AI software platform in Q3 and advancing its Butterfly HomeCare solution.

Butterfly Network (NYSE:BFLY), a digital health company specializing in portable ultrasound technology, will report its second quarter 2025 financial results on August 1, 2025, before market opens.

The company will host a conference call and webcast at 8:00 AM ET on the same day, featuring CEO Joseph DeVivo and CFO Heather Getz to discuss financial performance and operational progress. The call will be available via webcast and telephone, with replay access until August 15, 2025.

Butterfly Network (NYSE: BFLY) announces progress in their request to revoke a lead exemption under the EU's RoHS Directive for ultrasound transducers. The European Commission has appointed Oeko-Institut to evaluate the Company's October 2024 submission to remove Annex IV n. 14, which allows lead in piezoelectric materials. The stakeholder consultation period runs from June 6 to August 1, 2025, with Oeko-Institut's recommendation expected by Q2 2026. If approved, implementation would take 12-18 months after the final Delegated Act. This initiative aligns with EU's sustainability goals and aims to modernize medical imaging standards.

Butterfly Network (NYSE: BFLY), a digital health company specializing in handheld whole-body ultrasound technology, has announced its participation in the William Blair 45th Annual Growth Stock Conference. The company's President, CEO, and Chairman, Joseph DeVivo, will deliver a presentation on June 5, 2025, at 8:00 am CT in Chicago. The presentation will be accessible via live webcast in the Events & Presentations section of Butterfly's investor website, with a replay option available afterward. Investors can arrange one-on-one meetings with Mr. DeVivo through their William Blair representatives.

Butterfly Network (NYSE: BFLY) reported strong Q1 2025 financial results with revenue of $21.2 million, up 20% year-over-year. The company reduced its Q1 net loss by 36% to $14.0 million and decreased net cash used in operations by 43%. U.S. revenue grew 24% to $16.6 million, while international revenue increased 9% to $4.6 million. Gross margin improved to 63.0% from 58.2%. The company successfully raised $81.7 million through a public offering in January 2025. Key operational highlights include expanded medical education adoption, growth in AI development partnerships to 23, progress in the Butterfly HomeCare congestive heart failure pilot program, and mainstream recognition through HBO Max's medical drama. The company reiterated its FY2025 guidance, expecting revenue of $96-100 million (20% growth) and adjusted EBITDA loss of $37-42 million.

Butterfly Network (NYSE: BFLY), a digital health company specializing in portable, semiconductor-based ultrasound technology, has scheduled its first quarter 2025 financial results announcement for May 2, 2025 before market opening.

The company will host a conference call and webcast at 8:00 am ET on the same day, featuring Joseph DeVivo, President, CEO and Chairman of the Board, alongside Heather Getz, EVP and Chief Financial and Operations Officer. The call will be available in listen-only mode through the company's Investor Relations website, with telephone access options for both domestic and international callers.

A replay of the call will remain accessible until May 15, 2025.

Butterfly Network (NYSE: BFLY) announced that its Butterfly iQ3 ultrasound device was prominently featured in Episodes 12 and 13 of HBO Max's medical drama 'The Pitt'. The show depicts the device being used in critical trauma scenarios, particularly during a mass casualty event where traditional cart-based ultrasound equipment was replaced with Butterfly's handheld devices.

The episodes showcase the device's versatility in performing EFAST exams, blood flow evaluations, internal bleeding detection, and intracranial pressure assessments. CEO Joseph DeVivo highlighted that Butterfly devices are present in all top 100 U.S. health systems, indicating widespread adoption of the technology.

The unpaid product placement demonstrates Butterfly's growing recognition in healthcare, with the brand name becoming a verb among clinicians, according to VP of Marketing Jennifer Huang. The feature emphasizes the increasing role of Point-of-Care Ultrasound (POCUS) technology across medical specialties.

Butterfly Network (NYSE: BFLY), a digital health company specializing in handheld whole-body ultrasound technology, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare MedTech & Services Virtual Conference on March 18, 2025.

The company's leadership, including Joseph DeVivo (President, CEO & Chairman) and Heather Getz (EVP & Chief Financial and Operations Officer), will engage in one-on-one investor meetings and participate in a Fireside Chat scheduled for 11:20am EDT. Investors can access the Fireside Chat webcast through the Events & Presentations section of Butterfly's investor website.

Butterfly Network (NYSE: BFLY) reported strong Q4 2024 results with record quarterly revenue of $22.4 million, representing 35% year-over-year growth. The company achieved significant financial improvements, reducing Q4 net loss by 59% and net cash used in operations by 76%.

Key Q4 metrics include:

• U.S. revenue up 32% to $14.5 million
• International revenue increased 19% to $5.5 million
• Product revenue grew 45% to $14.7 million
• Gross margin improved to 61.4%

The company successfully completed a public offering in January 2025, raising $81.7 million in net proceeds. Looking ahead, Butterfly provided FY2025 guidance of $96-100 million in revenue (approximately 20% growth) and adjusted EBITDA loss of $37-42 million.